Notice

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at USA.gov.

Video: Taking HIV to the Gut

NIAID Now | October 04, 2017

How HIV Hijacks the Cellular Protein Alpha-4 Beta-7

During the early stages of infection, HIV mounts a severe and prolonged attack on the gut, which harbors a rich population of CD4+ T cells—the main type of immune cell that HIV infects and destroys. These cells are directed to and retained in the gut through the action of a protein on their surfaces called alpha-4 beta-7 integrin.

Earlier this year, NIAID scientists reported that alpha-4 beta-7 also is present on the surface of HIV itself. When newly forming HIV emerges from an infected cell producing alpha-4 beta-7, it carries the integrin along and incorporates it into its viral membrane. Like immune cells bearing alpha-4 beta-7, HIV bearing this protein is directed into and retained in the immune tissues in the gut. In this way, the virus hijacks a cellular protein to sharpen its assault on the immune system. Watch a two-minute animation describing the process:

 

These insights help explain earlier findings showing that treatment with an antibody targeting alpha-4 beta-7 led to sustained viral remission in monkeys infected with an HIV-like virus. NIAID researchers now are conducting an early-stage clinical trial in humans to determine whether short-term treatment with the anti-alpha-4 beta-7 antibody vedolizumab, which is FDA-approved to treat inflammatory bowel diseases, can induce sustained viral remission in people living with HIV. 

Reference: C Guzzo, D Ichikawa et al. Virion incorporation of integrin α4β7 facilitates HIV-1 infection and intestinal homing. Science Immunology DOI: 10.1126/sciimmunol.aam7341 (2017)

Content last reviewed on October 4, 2017